Pre-Surgical Immunotherapy Identifies Potential Benefit, Risk of Recurrence in Melanoma – Curetoday.com
|
Pre-Surgical Immunotherapy Identifies Potential Benefit, Risk of Recurrence in Melanoma
Curetoday.com For patients with melanoma, administration of a PD-1 checkpoint blockade therapy in the neoadjuvant setting – meaning it was given before the main treatment – could result in improved outcomes, according to study results presented at the 2018 American … |
